Oncology
Clinical research includes hematologic malignancies and solid malignancies, with attention to long-term outcomes after CAR cellular therapy for cancer.
- Hematologic malignancy
- Solid malignancy
- CAR cellular therapy
These studies focus on malignant disease settings where engineered cell therapies are being evaluated for durable therapeutic activity.
Autoimmune Disease
The sponsor also funds research in refractory autoimmune disease, including relapsed/refractory hematologic autoimmune disease and systemic immune-mediated conditions.
- Refractory autoimmune disease
- Relapsed/refractory hematologic autoimmune disease
- Immune-mediated disease
This area reflects interest in advanced therapies for difficult-to-treat autoimmune disorders with limited treatment options.
Rheumatology
Trials extend into systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy, covering severe rheumatic diseases with immune dysregulation.
- Systemic lupus erythematosus
- Systemic sclerosis
- Idiopathic inflammatory myopathy
These programs align with therapeutic interest in complex inflammatory and connective tissue disorders.
Cellular Immunotherapy
Across its active studies, the sponsor is engaged in engineered cell therapy for both malignant and autoimmune conditions, with a focus on CRISPR-based CAR therapies.
- Engineered cell therapy
- CRISPR-based CAR therapies
- Immune cell engineering
This work spans therapeutic areas where precise immune modulation is central to treatment development.
